Atle Fund Management AB
Atle Fund Management AB reported 39 holdings worth US$372M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Jul 24, 2026
Atle Fund Management AB reported 39 holdings worth US$372M as of Jun 30, 2026. Largest: Eli Lilly And Company, Merck & Company, Inc. and Johnson & Johnson. Filed Jul 24, 2026 (Form 13F).
- Holdings
- 39
- Value as reported
- US$372M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Eli Lilly And Company | 29,821 | US$35.8M | 9.6% |
| Merck & Company, Inc. | 189K | US$24.3M | 6.5% |
| Johnson & Johnson | 85,425 | US$21.7M | 5.8% |
| Abbvie Inc. | 64,325 | US$16.2M | 4.4% |
| Cvs Health Corporation | 146K | US$15.1M | 4.1% |
| Thermo Fisher Scientific Inc | 27,859 | US$14M | 3.8% |
| Revolution Medicines, Inc. | 73,077 | US$13.7M | 3.7% |
| Biogen Inc. | 62,781 | US$13.6M | 3.6% |
| Neurocrine Biosciences, Inc. | 72,898 | US$12.3M | 3.3% |
| Mirum Pharmaceuticals, Inc. | 101K | US$11.8M | 3.2% |
| Ionis Pharmaceuticals, Inc. | 137K | US$10.9M | 2.9% |
| Beone Medicines Ltd. Class A | 35,180 | US$10M | 2.7% |
| Intuitive Surgical, Inc. | 24,656 | US$9.81M | 2.6% |
| Stryker Corporation | 30,283 | US$9.53M | 2.6% |
| Vertex Pharmaceuticals Incorporated | 19,131 | US$9.5M | 2.6% |
| Edwards Lifesciences Corporation | 103K | US$9.34M | 2.5% |
| Bridgebio Pharma, Inc. | 125K | US$9.29M | 2.5% |
| Krystal Biotech, Inc. | 24,019 | US$8.93M | 2.4% |
| Cencora, Inc. | 31,126 | US$8.81M | 2.4% |
| Abivax Sa | 58,170 | US$7.75M | 2.1% |
| Incyte Corporation | 56,953 | US$6.46M | 1.7% |
| Irhythm Holdings, Inc. | 54,102 | US$6.44M | 1.7% |
| Boston Scientific Corporation | 146K | US$6.25M | 1.7% |
| Insmed Incorporated | 58,378 | US$6.22M | 1.7% |
| Tango Therapeutics, Inc. | 199K | US$6.21M | 1.7% |
| Gilead Sciences, Inc. | 46,142 | US$5.83M | 1.6% |
| Cardinal Health, Inc. | 23,630 | US$5.61M | 1.5% |
| Oruka Therapeutics, Inc. | 54,886 | US$5.22M | 1.4% |
| Spyre Therapeutics, Inc. | 57,030 | US$5.06M | 1.4% |
| Dexcom, Inc. | 71,846 | US$4.84M | 1.3% |
| Bicara Therapeutics Inc. | 146K | US$4.32M | 1.2% |
| Ideaya Biosciences, Inc. | 94,478 | US$3.52M | 0.95% |
| Celcuity Inc. | 33,313 | US$3.49M | 0.94% |
| Disc Medicine, Inc. | 43,682 | US$3.19M | 0.86% |
| Pyxis Oncology, Inc. | 966K | US$2.91M | 0.78% |
| Compass Therapeutics, Inc. | 1.05M | US$2.3M | 0.62% |
| Jade Biosciences, Inc. | 88,556 | US$1.97M | 0.53% |
| Amgen Inc. | 0 | US$0 | 0.00% |
| Soleno Therapeutics, Inc. | 0 | US$0 | 0.00% |
| Unitedhealth Group Incorporated | 0 | US$0 | 0.00% |
Source
View original at SEC
Related